Research Article
No access
Published Online: 23 September 2005

Comparison of the Aerosol Velocity and Spray Duration of Respimat® Soft Mist™ Inhaler and Pressurized Metered Dose Inhalers

Publication: Journal of Aerosol Medicine
Volume 18, Issue Number 3

Abstract

Apart from particle size distribution, spray velocity is one of the most important aerosol characteristics that influence lung deposition of inhaled drugs. The time period over which the aerosol is released (spray duration) is also important for coordination of inhalation. Respimat ® Soft Mist™ Inhaler (SMI) is a new generation, propellant-free inhaler that delivers drug to the lung much more efficiently than pressurised metered dose inhalers (pMDIs). The objective of this study was to compare the velocity and spray duration of aerosol clouds produced by Respimat® SMI with those from a variety of chlorofluorocarbon (CFC) and hydrofluoroalkane (HFA) pMDIs. All inhalers contained solutions or suspensions of bronchodilators. A videorecording method was used to determine the aerosol velocity. For spray duration, the time for generation of the Soft Mist™ by Respimat® SMI was initially determined using three different methods (videorecording [techniques A and B], laser light diffraction and rotating disc). Videorecording was then used to compare the spray duration of Respimat® SMI with those from the other inhalers. The Soft Mist™ produced by Respimat® SMI moved much more slowly and had a more prolonged duration than aerosol clouds from pMDIs (mean velocity at a 10-cm distance from the nozzle: Respimat® SMI, 0.8 m/sec; pMDIs, 2.0–8.4 m/sec; mean duration: Respimat® SMI, 1.5 sec; pMDIs, 0.15–0.36 sec). These characteristics should result in improved lung and reduced oropharyngeal deposition, and are likely to simplify coordination of inhaler actuation and inhalation compared with pMDIs.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

cover image Journal of Aerosol Medicine
Journal of Aerosol Medicine
Volume 18Issue Number 3Fall 2005
Pages: 273 - 282
PubMed: 16181002

History

Published online: 23 September 2005
Published in print: Fall 2005

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Dieter Hochrainer
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Hubert Hölz
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Christoph Kreher
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Luigi Scaffidi
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Michael Spallek
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Herbert Wachtel
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/EPUB

Figures

Tables

Media

Share

Share

Copy the content Link

Share on social media

Back to Top